Stefanie Heynck

发表

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

K. Cibulskis, J. Shendure, G. Getz, 2012, Nature Genetics.

Telomerase activation by genomic rearrangements in high-risk neuroblastoma

Simon C Watkins, F. Westermann, F. Berthold, 2015, Nature.

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

William Pao, Michael Hölzel, Martin Peifer, 2011, Clinical Cancer Research.

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.

Laura Tolosi, Michael Peyton, Thomas Zander, 2009, The Journal of clinical investigation.

A framework for identification of actionable cancer genome dependencies in small cell lung cancer

Herbert Waldmann, Takashi Ninomiya, Martin Peifer, 2012, Proceedings of the National Academy of Sciences.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

M. Meyerson, I. Petersen, R. Onofrio, 2011, Cancer discovery.

in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

Mutations in the DDR 2 Kinase Gene identify a Novel therapeutic target in squamous cell lung cancer

M. Meyerson, I. Petersen, R. Onofrio, 2011 .

Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.

M. Sos, C. Grütter, D. Rauh, 2011, Bioorganic & medicinal chemistry.

Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.

Roman K. Thomas, M. Sos, W. V. van Otterlo, 2010, Journal of medicinal chemistry.

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.

Martin Peifer, Daniel Rauh, Lars Ruddigkeit, 2010, Cancer research.

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

William Pao, Thomas Zander, Martin Peifer, 2009, Proceedings of the National Academy of Sciences.

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.

M. Meyerson, C. Mermel, B. Weir, 2009, Cancer research.

Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling

Martin Peifer, Daniel Rauh, Jörg Rahnenführer, 2010, PloS one.

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.

Roman K. Thomas, M. Sos, Anu Gupta, 2013, Journal of medicinal chemistry.

Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

I. Petersen, R. Beroukhim, H. Groen, 2010, Science Translational Medicine.